Please assess the completion status of the following clinical trial:

Trial Title: A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Adults with either active or a history of non-valvular atrial fibrillation or flutter with the planned or existing use of an oral anticoagulant for prophylaxis of thromboembolism. In addition, subjects must have had an acute coronary syndrome or percutaneous coronary intervention with a stent within the prior 14 days~* Planned use of antiplatelet agents for at least 1 to 6 months~* Males and Females ≥ 18 years of age~* Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug~Exclusion Criteria:~* Conditions other than atrial fibrillation that require chronic anticoagulation. (e.g. prosthetic mechanical heart valve)~* Severe renal insufficiency (serum creatinine \> 2.5 mg/dL or a calculated creatinine clearance \< 30 mL/min~* Patients with a history of intracranial hemorrhage~* Patients have had or will undergo Coronary arterial bypass graft (CABG) for their index acute coronary syndrome (ACS) event~* Patients with known ongoing bleeding and patients with known coagulopathies~* Any contraindications or allergies to VKA, apixaban, or to intended P2Y12 antagonists or to aspirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: ACTIVE_COMPARATOR): 5 mg or 2.5 mg Apixaban tablets orally twice per day
- Vitamin K Antagonist (Type: ACTIVE_COMPARATOR): VKA tablets orally once daily
- Acetylsalicylic acid film coated tablet (Type: PLACEBO_COMPARATOR): 81 mg Acetylsalicylic acid film coated tablet orally once daily
- Placebo matching Acetylsalicylic acid film coated tablet (Type: PLACEBO_COMPARATOR): Placebo matching Acetylsalicylic acid film coated tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).